Genetic Study of Familial Factors in Patients With Colon Cancer

Familial Factors in the Development of Colon Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00055848

Enrollment

600

Registered

2003-03-07

Start date

2001-12-31

Completion date

2010-10-31

Last updated

2016-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

adenocarcinoma of the colon, stage I colon cancer, stage II colon cancer, stage III colon cancer, stage IV colon cancer

Brief summary

RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Clinical trial to study the cancer-related genes in patients who have colon cancer or adenomatous polyps.

Detailed description

OBJECTIVES: * Identify human colon neoplasia susceptibility genes in patients with colon cancer or adenomatous polyps. * Correlate the inheritance of novel susceptibility alleles for adenomatous polyposis of the colon with colon neoplasia in these patients. * Correlate colon neoplasia susceptibility with the presence of COX-2, sPLA2, and DNMT genes in these patients. * Identify a novel gene that governs increased susceptibility to colon adenoma and cancer in the genome of these patients.

Interventions

GENETICcytogenetic analysis

GENETICgene mapping

GENETICmicroarray analysis

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 70 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of colon cancer or polyps at age 70 or under * Has a living full sibling with diagnosis of colon cancer or polyps at age 70 or under * No history of familial adenomatous polyposis syndrome * No hereditary nonpolyposis colon cancer, according to Amsterdam criteria * No known I1370K adenomatous polyposis of the colon susceptibility variant * Enrolled on 1 of the following clinical trials: * CLB-9581 * CLB-89803 * CLB-80001 NOTE: Patients do not need to be receiving protocol therapy. Patients who are outside the treatment protocol's follow-up range are eligible. Patients who discontinued therapy for any reason, including toxic effects, are eligible. PATIENT CHARACTERISTICS: Age * 70 and under at diagnosis Other * No significant psychiatric illness that would preclude giving informed consent * No inflammatory bowel disease (in patient or sibling)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026